China
A study of China's drug market has found evidence of significant changes, including a large fall in traditional Chinese medicine use (22% from 1999 to 2003). Marks & Clark, a European patent and trade mark law firm, produced its China report to study patent filing in the automobile, drugs and telecommunications sectors.
In the Asia-Pacific region, the report notes that, in 1998, only the Chinese Academy of Sciences was among the top 10 patent filers, out of all Chinese institutions. By 2003, seven of the top 10 were Chinese, including the top five.
Tim Andrews, a partner at the law firm, commented on the trend: "Chinese companies still have a long way to go in the pharmaceuticals sector to challenge western dominance. Most of China's top patent filers are academic institutions."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze